Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

•Favipiravir is an oral RNA-dependent RNA polymerase inhibitor.•Favipiravir is under investigation in many countries for the treatment of COVID-19.•We evaluated favipiravir’s efficacy and safety in mild-to-moderate COVID-19.•Favipiravir treatment led to significant improvement in time to clinical cure.•Favipiravir may be a safe and effective treatment in mild-to-moderate COVID-19.